Biotech company launches multi-cancer detection test

• Guardant Health's Q2 revenue of $335M beat estimates, driven by a 257% year-over-year increase in Shield cancer screening revenue ($52.9M).
• UnitedHealth Group will now cover Guardant Health's Shield blood test for colorectal cancer screening, significantly expanding access.
• The company's Infinity AI platform is key to developing multi-cancer detection tools and expanding into multi-disease screening, representing a potential $300 billion market opportunity.
• Guardant Health stock (GH) is up over 5% intraday and more than 250% over the last year, with profitability expected by Q4 2027.

Guardant Health (GH) reported strong Q2 results, beating revenue estimates and seeing significant growth in its Shield colorectal cancer screening test. The company's Infinity AI platform is driving innovation, leading to a multi-cancer detection tool and a positive outlook for future expansion into broader disease screening, with profitability targeted by Q4 2027.